198 related articles for article (PubMed ID: 35506446)
1. Successful use of empagliflozin to treat neutropenia in two G6PC3-deficient children: Impact of a mutation in SGLT5.
Boulanger C; Stephenne X; Diederich J; Mounkoro P; Chevalier N; Ferster A; Van Schaftingen E; Veiga-da-Cunha M
J Inherit Metab Dis; 2022 Jul; 45(4):759-768. PubMed ID: 35506446
[TBL] [Abstract][Full Text] [Related]
2. SGLT5 is the renal transporter for 1,5-anhydroglucitol, a major player in two rare forms of neutropenia.
Diederich J; Mounkoro P; Tirado HA; Chevalier N; Van Schaftingen E; Veiga-da-Cunha M
Cell Mol Life Sci; 2023 Aug; 80(9):259. PubMed ID: 37594549
[TBL] [Abstract][Full Text] [Related]
3. DBS are suitable for 1,5-anhydroglucitol monitoring in GSD1b and G6PC3-deficient patients taking SGLT2 inhibitors to treat neutropenia.
Dewulf JP; Chevalier N; Marie S; Veiga-da-Cunha M
Mol Genet Metab; 2023 Nov; 140(3):107712. PubMed ID: 38353183
[TBL] [Abstract][Full Text] [Related]
4. SLGT2 Inhibitor Rescues Myelopoiesis in G6PC3 Deficiency.
Hiwarkar P; Bargir U; Pandrowala A; Bodhanwala M; Thakker N; Taur P; Madkaikar M; Desai M
J Clin Immunol; 2022 Nov; 42(8):1653-1659. PubMed ID: 35838821
[TBL] [Abstract][Full Text] [Related]
5. Treatment of the Neutropenia Associated with GSD1b and G6PC3 Deficiency with SGLT2 Inhibitors.
Veiga-da-Cunha M; Wortmann SB; Grünert SC; Van Schaftingen E
Diagnostics (Basel); 2023 May; 13(10):. PubMed ID: 37238286
[TBL] [Abstract][Full Text] [Related]
6. Failure to eliminate a phosphorylated glucose analog leads to neutropenia in patients with G6PT and G6PC3 deficiency.
Veiga-da-Cunha M; Chevalier N; Stephenne X; Defour JP; Paczia N; Ferster A; Achouri Y; Dewulf JP; Linster CL; Bommer GT; Van Schaftingen E
Proc Natl Acad Sci U S A; 2019 Jan; 116(4):1241-1250. PubMed ID: 30626647
[TBL] [Abstract][Full Text] [Related]
7. Treating neutropenia and neutrophil dysfunction in glycogen storage disease type Ib with an SGLT2 inhibitor.
Wortmann SB; Van Hove JLK; Derks TGJ; Chevalier N; Knight V; Koller A; Oussoren E; Mayr JA; van Spronsen FJ; Lagler FB; Gaughan S; Van Schaftingen E; Veiga-da-Cunha M
Blood; 2020 Aug; 136(9):1033-1043. PubMed ID: 32294159
[TBL] [Abstract][Full Text] [Related]
8. Favorable outcome of empagliflozin treatment in two pediatric glycogen storage disease type 1b patients.
Hexner-Erlichman Z; Veiga-da-Cunha M; Zehavi Y; Vadasz Z; Sabag AD; Tatour S; Spiegel R
Front Pediatr; 2022; 10():1071464. PubMed ID: 36507137
[TBL] [Abstract][Full Text] [Related]
9. Treatment recommendations for glycogen storage disease type IB- associated neutropenia and neutrophil dysfunction with empagliflozin: Consensus from an international workshop.
Grünert SC; Derks TGJ; Mundy H; Dalton RN; Donadieu J; Hofbauer P; Jones N; Uçar SK; LaFreniere J; Contreras EL; Pendyal S; Rossi A; Schneider B; Spiegel R; Stepien KM; Wesol-Kucharska D; Veiga-da-Cunha M; Wortmann SB
Mol Genet Metab; 2024 Mar; 141(3):108144. PubMed ID: 38277989
[TBL] [Abstract][Full Text] [Related]
10. Type I glycogen storage diseases: disorders of the glucose-6-phosphatase/glucose-6-phosphate transporter complexes.
Chou JY; Jun HS; Mansfield BC
J Inherit Metab Dis; 2015 May; 38(3):511-9. PubMed ID: 25288127
[TBL] [Abstract][Full Text] [Related]
11. Empagliflozin for treating neutropenia and neutrophil dysfunction in 21 infants with glycogen storage disease 1b.
Grünert SC; Gautschi M; Baker J; Boyer M; Burlina A; Casswall T; Corpeleijn W; Çıki K; Cotter M; Crushell E; Derks TGJ; Haas D; Kilavuz S; Kingma SDK; Korman SH; Kozek A; de Laet C; Mundy H; Nassogne MC; Quintero V; Rossi A; Spenger J; Spiegel R; Stephenne X; Stojkov D; Tal G; Veiga-da Cunha M; Wortmann SB
Mol Genet Metab; 2024 Jun; 142(2):108486. PubMed ID: 38733639
[TBL] [Abstract][Full Text] [Related]
12. Improved inflammatory bowel disease, wound healing and normal oxidative burst under treatment with empagliflozin in glycogen storage disease type Ib.
Grünert SC; Elling R; Maag B; Wortmann SB; Derks TGJ; Hannibal L; Schumann A; Rosenbaum-Fabian S; Spiekerkoetter U
Orphanet J Rare Dis; 2020 Aug; 15(1):218. PubMed ID: 32838757
[TBL] [Abstract][Full Text] [Related]
13. Severe congenital neutropenia resulting from G6PC3 deficiency with increased neutrophil CXCR4 expression and myelokathexis.
McDermott DH; De Ravin SS; Jun HS; Liu Q; Priel DA; Noel P; Takemoto CM; Ojode T; Paul SM; Dunsmore KP; Hilligoss D; Marquesen M; Ulrick J; Kuhns DB; Chou JY; Malech HL; Murphy PM
Blood; 2010 Oct; 116(15):2793-802. PubMed ID: 20616219
[TBL] [Abstract][Full Text] [Related]
14. Clinical spectrum, over 12-year follow-up and experience of SGLT2 inhibitors treatment on patients with glycogen storage disease type Ib: a single-center retrospective study.
Shao YX; Liang CL; Su YY; Lin YT; Lu ZK; Lin RZ; Zhou ZZ; Zeng CH; Tao CY; Liu ZC; Zhang W; Liu L
Orphanet J Rare Dis; 2024 Apr; 19(1):155. PubMed ID: 38605407
[TBL] [Abstract][Full Text] [Related]
15. Lack of glucose recycling between endoplasmic reticulum and cytoplasm underlies cellular dysfunction in glucose-6-phosphatase-beta-deficient neutrophils in a congenital neutropenia syndrome.
Jun HS; Lee YM; Cheung YY; McDermott DH; Murphy PM; De Ravin SS; Mansfield BC; Chou JY
Blood; 2010 Oct; 116(15):2783-92. PubMed ID: 20498302
[TBL] [Abstract][Full Text] [Related]
16. Understanding the role of SGLT2 inhibitors in glycogen storage disease type Ib: the experience of one UK centre.
Halligan RK; Dalton RN; Turner C; Lewis KA; Mundy HR
Orphanet J Rare Dis; 2022 May; 17(1):195. PubMed ID: 35549996
[TBL] [Abstract][Full Text] [Related]
17. Current understanding on pathogenesis and effective treatment of glycogen storage disease type Ib with empagliflozin: new insights coming from diabetes for its potential implications in other metabolic disorders.
Maiorana A; Tagliaferri F; Dionisi-Vici C
Front Endocrinol (Lausanne); 2023; 14():1145111. PubMed ID: 37152929
[TBL] [Abstract][Full Text] [Related]
18. Glycogen storage disease type Ib neutrophils exhibit impaired cell adhesion and migration.
Kim GY; Lee YM; Kwon JH; Jun HS; Chou J
Biochem Biophys Res Commun; 2017 Jan; 482(4):569-574. PubMed ID: 27864142
[TBL] [Abstract][Full Text] [Related]
19. A clinical and molecular review of ubiquitous glucose-6-phosphatase deficiency caused by G6PC3 mutations.
Banka S; Newman WG
Orphanet J Rare Dis; 2013 Jun; 8():84. PubMed ID: 23758768
[TBL] [Abstract][Full Text] [Related]
20. G6PC3 mutations are associated with a major defect of glycosylation: a novel mechanism for neutrophil dysfunction.
Hayee B; Antonopoulos A; Murphy EJ; Rahman FZ; Sewell G; Smith BN; McCartney S; Furman M; Hall G; Bloom SL; Haslam SM; Morris HR; Boztug K; Klein C; Winchester B; Pick E; Linch DC; Gale RE; Smith AM; Dell A; Segal AW
Glycobiology; 2011 Jul; 21(7):914-24. PubMed ID: 21385794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
